PHARMACY **BENEFACT**

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS®

Admelog added to the Alberta Biosimilar Initiative

On December 12, 2019, the Alberta government introduced the Alberta Biosimilar Initiative (refer to Benefact 826, December 2019.) This communication is to inform you that as of August 1, 2021, a biosimilar drug, Admelog, will be listed on the *Alberta Drug Benefit List (ADBL)* and will be subject to the Alberta Biosimilar Initiative.

Switching to a biosimilar

Effective August 1, 2021, adult patients currently taking the originator drug product, Humalog, are required to switch to a biosimilar version by February 1, 2022, to maintain coverage for this molecule through their Alberta government-sponsored drug plan. Humalog will not be eligible for coverage for new insulin lispro starts. All new patient starts for insulin lispro will be covered for the biosimilar.

Exceptions

Please note, if one of these exceptions apply to your patients, they will continue to be eligible for Humalog.

- Patients that require access to Humalog because their insulin pump has not yet been approved for use with the biosimilar should have their physician submit an exception request. Patients enrolled in the Alberta Insulin Pump Therapy Program (IPTP) and using a Medtronic insulin pump do not need to submit an exception request as an exemption will be in place until the biosimilar is approved for use.
- Pregnant patients: A Biosimilar Initiative Exception Request form must be submitted. Requests for Humalog may be submitted by pharmacists with additional prescribing authorization. Alberta Blue Cross will only consider approval based on pregnancy and approval will be granted until six months past the delivery due date. Those that are trying to conceive will not be approved.
- Pediatric patients: existing Humalog pediatric patients (under the age of 18 years) are exempt from switching. No application is required.
- Those who have been approved for a biologic exception due to a medical reason. If there is a medical reason why a patient cannot switch to the biosimilar, the prescriber can submit a request for exceptional coverage to Alberta Blue Cross. Requests will be reviewed on a case-by-case basis.

For the most current coverage status, please visit the Interactive Drug Benefit List at **idbl.ab.bluecross. ca/idbl/load.do** and search the drug name. Please visit **Alberta Health** online at **alberta.ca/biosimilar-drugs.aspx** for a current list of biologics, their biosimilar equivalents and specific indications affected by this policy. As a reminder, supporting materials for patients and health-care providers regarding the Alberta Biosimilar Initiative are available on the Alberta Blue Cross website at **ab.bluecross.ca/pdfs/Biosimilars-Resources-for-Patients.pdf**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area) 403-294-4041 (Calgary and area) 1-800-361-9632 (toll free) FAX 780-498-8406 (Edmonton and area) FAX 1-877-305-9911 (toll free)



Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.971 2021/07